Trial · NCT04781647
Results by group226
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 226
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With an Adverse Event | ABI-H0731 + ETV | 14 | Participants | ||
| Number of Participants With an Adverse Event | ABI-H0731 + ETV + Peg-IFNα | 17 | Participants | ||
| Number of Participants With an Adverse Event | ETV + Peg-IFNα | 17 | Participants | ||
| Number of Participants With Premature Discontinuation of Treatment | ABI-H0731 + ETV | 18 | Participants | ||
| Number of Participants With Premature Discontinuation of Treatment | ABI-H0731 + ETV + Peg-IFNα | 17 | Participants | ||
| Number of Participants With Premature Discontinuation of Treatment | ETV + Peg-IFNα | 11 | Participants | ||
| Number of Participants With a Laboratory Abnormality | ABI-H0731 + ETV | 19 | Participants | ||
| Number of Participants With a Laboratory Abnormality | ABI-H0731 + ETV + Peg-IFNα | 16 | Participants | ||
| Number of Participants With a Laboratory Abnormality | ETV + Peg-IFNα | 17 | Participants | ||
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV | Week 1 | -1.3 | Standard Deviation .51 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV + Peg-IFNα | Week 1 | -1.5 | Standard Deviation .69 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ETV + Peg-IFNα | Week 1 | -.5 | Standard Deviation .43 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV | Week 2 | -1.6 | Standard Deviation .58 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV + Peg-IFNα | Week 2 | -1.9 | Standard Deviation .79 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ETV + Peg-IFNα | Week 2 | -.6 | Standard Deviation .61 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV | Week 4 | -2.0 | Standard Deviation .72 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV + Peg-IFNα | Week 4 | -2.2 | Standard Deviation .74 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ETV + Peg-IFNα | Week 4 | -.9 | Standard Deviation .70 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV | Week 6 | -2.3 | Standard Deviation .87 | log10 U/mL |
| Mean Change From Baseline in HBV pgRNA | ABI-H0731 + ETV + Peg-IFNα | Week 6 | -2.6 | Standard Deviation .67 | log10 U/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04781647/results